Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Gregory G SchwartzStephen J NichollsPeter P TothMichael SweeneyChristopher HallidayJan O JohanssonNorman C W WongEwelina KulikowskiKamyar Kalantar-ZadehHenry N GinsbergKausik K RayPublished in: Cardiovascular diabetology (2021)
Insulin-treated patients with T2D, low HDL cholesterol, and ACS are at high risk for recurrent MACE despite the use of evidence-based, contemporary therapies. A strong association of insulin treatment with risk of MACE persists after adjustment for other characteristics associated with MACE. There is unmet need for additional treatments to mitigate this risk. Trial registration ClinicalTrials.gov NCT02586155, registered October 26, 2015.
Keyphrases
- type diabetes
- acute coronary syndrome
- cardiovascular events
- glycemic control
- cardiovascular disease
- coronary artery disease
- clinical trial
- insulin resistance
- percutaneous coronary intervention
- emergency department
- randomized controlled trial
- adipose tissue
- study protocol
- metabolic syndrome
- skeletal muscle
- phase iii
- electronic health record